Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 87 of 5804
-
Bleeding stroke drug shows promise in Fast-Action trial
Disease control OngoingThe objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The centra…
Phase: PHASE3 • Sponsor: Joseph Broderick, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New shot could cut bleeding episodes for hemophilia a patients
Disease control CompletedThis study is investigating how Mim8 works compared to other medicines in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the mis…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors
Disease control OngoingThis study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach …
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for severe lung disease: drug delays death and hospitalization
Disease control CompletedThe objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension \[PAH\] therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first e…
Phase: PHASE3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Major study tests moderna vaccine in High-Risk groups
⭐️ VACCINE ⭐️ CompletedThe study will evaluate the clinical efficacy of different dosing regimens of the Moderna COVID-19 mRNA vaccine (100 mcg) in preventing COVID-19 disease in people who are living with HIV or have comorbidities associated with elevated risk of severe COVID-19, with the different va…
Phase: PHASE2, PHASE3 • Sponsor: COVID-19 Prevention Network • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New pill may cut transfusions for thalassemia patients
Disease control OngoingThe primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Phase: PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New RSV shot shows promise for protecting vulnerable babies
Prevention CompletedThis study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
New drug could extend window for treating deadly stroke
Disease control Recruiting nowPatients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be rando…
Phase: PHASE2, PHASE3 • Sponsor: University of Melbourne • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Breakthrough shot shields babies from deadly RSV
Prevention CompletedThe purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Artificial heart trial aims to keep patients alive until transplant
Disease control Recruiting nowThe safety and performance of the Aeson TAH system have been demonstrated for the CE mark approval in December 2020. The purpose of this post-market clinical investigation is to confirm the safety, performance and effectiveness of the Aeson TAH system when used in routine care by…
Sponsor: Carmat SAS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control OngoingThe purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advance…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could steroids help kids recover from stroke?
Disease control Recruiting nowThis clinical trial deals with focal cerebral arteriopathy and childhood stroke, a rare but devastating condition. Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection and there is increasing evidence that inflammatory processes play a c…
Phase: PHASE3 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Gene therapy breakthrough? new treatment aims to fix sickle cell at the source
Disease control Recruiting nowThis study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficac…
Phase: PHASE1, PHASE2 • Sponsor: Kamau Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill combo shows promise for tough thyroid cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodi…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo pill shows promise for Tough-to-Treat schizophrenia
Disease control CompletedThis is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adj…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to outperform standard care in tough colorectal cancer
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy could free GSD ia patients from constant cornstarch
Disease control CompletedThe primary objectives of this study are to evaluate the efficacy of DTX401 to reduce or eliminate dependence on exogenous glucose replacement therapy to maintain euglycemia and to maintain or improve the quality of glucose control.
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for rare, aggressive thyroid cancer: drug combo shows promise
Disease control OngoingThis phase II trial studies how well lenvatinib and pembrolizumab work in treating patients with anaplastic thyroid cancer that is stage IVB and has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable), or stage IVC that has sp…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Radioactive seeds plus immunotherapy: a new hope for Hard-to-Treat head and neck cancer?
Disease control Recruiting nowA unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for older leukemia patients: targeted drug combo shows promise
Disease control OngoingThe safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab a…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC